DL Holdings' digital finance development strategy will be implemented in three phases: In the first phase, DL will establish a licensed virtual asset over-the-counter (VA OTC) and prime brokerage ...

HONG KONG SAR - Media OutReach Newswire - 24 July 2025 - Recently, DL Holdings Group (1709.HK) has entered into strategic cooperation agreements with ViaBTC, Asseto, and Rich Dragon Consultants, while ...

BMRCL plans Phase-3 of Namma Metro, possibly affecting over 11,000 trees. Public consultations start to discuss tree cutting, shifting, and route alignment.

Cipher Mining’s (CIFR) Black Pearl Phase I Surpasses Guidance, Reaches a Self-Mining Capacity of Around 3.4 EH/s Published on July 22, 2025 at 11:13 am by Noor Ul Ain Rehman in News ...

Bengaluru: Bengaluru Metro Rail Corporation Ltd (BMRCL) officials Monday clarified that the tree loss during the construction of Namma Metro Phase 3 w.

About the EFZO-FIT™ Study EFZO-FIT™ is a global Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of efzofitimod in patients with pulmonary sarcoidosis.

The bags from the supermarket chain are becoming increasingly popular, even though the store doesn’t operate in Britain.

The SRM Institute of Science and Technology has been released the phase 3 result 2025 on its official website at srmist.edu.in. Check result using registration ID and password.

Ultragenyx shares fall after Phase 3 study misses interim target, but analysts remain positive ahead of final OI data expected later this year.

Known for its quick reload and solid design, the Model 3 became a trusted sidearm around the world. Learn how it helped build Smith & Wesson’s legacy.

SRMJEEE Phase 3 Result 2025: The SRM Institute of Science and Technology (SRMIST) has shared the date for the announcement of the SRMJEEE 2025 phase 3 results. The result will come out tomorrow, July ...

--Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc, today announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 in pediatric and young ...